Americans' becoming more aware of GLP-1 drugs like Ozempic, Wegovy: Survey
The YouGov poll, released Friday, shows that at least 80 percent of respondents have heard at least 'a little bit' about semaglutide, a medication used to treat Type 2 diabetes that also helps a user to shed weight.
In March 2023, only 60 percent of Americans were aware of the drug. A year later, in March 2024, that number had jumped to 70 percent, the pollster noted. The latest survey also shows that the share of those who have heard 'a lot' about the medication has nearly doubled since 2023, increasing to 41 percent from 23 percent.
Just 36 percent of respondents say they know someone who has taken semaglutide. Around 14 percent listed a family member took the medicine, 16 percent named a friend, 11 percent identified an acquaintance and 7 percent said they had taken it themselves, according to the poll. Several also noted they knew a user in more than one category.
Women are more likely than men, 43 percent to 29 percent, to know someone — including themselves — who has taken a GLP-1 agonist drug, per the survey.
The weight loss medications — including Wegovy, Ozempic, Zepbound and others — have been available since 2005 but have only in the past few years been used to treat obesity. The drugs work by mimicking a hormone in the body — glucagon-like peptide-1 — that stimulates insulin secretion and reduces appetite.
Possible side effects of taking the medication include nausea, diarrhea, vomiting, and constipation.
While semaglutide is currently only prescribed for weight loss or treating diabetes, early research is pointing to possible benefits for a host of other issues, including treatment for addiction, neurodegenerative diseases and conditions that affect the heart, kidney or liver.
The latest survey found that roughly a quarter of respondents said they would be 'very' or 'somewhat' interested in taking the medication as a weight loss treatment.
About a third of Americans have either taken the drug or said they would be interested in trying it. On the other side, about 17 percent said they were 'not very' interested in the medication and 45 percent signaled they were not at all interested.
A separate poll from last September found that around a quarter of adults in the U.S. would consider using weight loss medications without consulting their doctor.
The YouGov analysis is based on an online survey conducted from May 22-25 among 1,109 adults in the U.S. The margin of error for the full sample is 4 percentage points.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Weight loss drugs could soon be used to treat these seven other health conditions
Blockbuster diabetes and weight loss drugs from Eli Lilly and Novo Nordisk - including Mounjaro, Zepbound, Ozempic and Wegovy - generated over U$40 billion in combined sales last year. However, Novo Nordisk has warned that the rise in copycat versions of its weight-loss drug in the U.S. and competition from Lilly across several markets is expected to hurt Wegovy sales this year. Both companies are actively exploring other medical uses for these GLP-1 drugs, aiming to broaden their market reach and secure wider health insurance coverage, a strategy that has already seen some success. Here are some of the other conditions the drugs are being used and tested for: Alcohol addiction A study conducted by the University of Copenhagen's Psychiatric Centre Rigshospitalet, is investigating whether semaglutide - the main ingredient in Wegovy and Ozempic - can help reduce alcohol intake in 108 patients diagnosed with alcohol use disorder and obesity. Alzheimer's disease Novo Nordisk is testing semaglutide in a late-stage trial in patients with early Alzheimer's disease. The study, which will enrol 1,840 patients, could have an initial data readout as early as later this year. Cardiovascular disease Eli Lilly was testing tirzepatide - the main ingredient in Mounjaro and Zepbound - for patients with heart failure and obesity. Lilly had said it would enrol about 700 people in the study, but the company said in May that it had withdrawn its U.S. application for heart failure approval. The European Medicines Agency backed the use of Novo's semaglutide to help ease heart failure symptoms in people with obesity in September 2024. Chronic kidney disease Novo's Ozempic is approved in the United States for reducing the risk of kidney failure and disease progression, as well as the risk of death due to heart problems in diabetes patients with chronic kidney disease. Lilly's tirzepatide is being evaluated in a mid-stage study of patients with chronic kidney disease and obesity. Lilly plans to enrol up to 140 participants with the study expected to be completed next year. Liver disease Novo is testing semaglutide in a late-stage trial of patients with a common, but difficult to treat, type of fatty liver disease called non-alcoholic steatohepatitis, or NASH. The study is expected to be completed in April 2029 and include about 1,200 patients. Lilly's tirzepatide helped up to 74 per cent of patients achieve absence of the disease with no worsening of liver scarring at 52 weeks, compared with 13 per cent of patients on placebo, in a mid-stage trial for NASH, which is also now referred to as metabolic dysfunction-associated steatohepatitis, or MASH. Neurological disorders Researchers at the Danish Headache Centre are testing semaglutide along with a very low-calorie diet as a treatment for new-onset idiopathic intracranial hypertension, a condition associated with obesity in which blood pressure inside the head rises. The study has enrolled about 50 patients and is expected to be completed in October 2025. Sleep apnea Zepbound was approved by the U.S. Food and Drug Administration for obstructive sleep apnea in December 2024, making it the first drug to directly treat patients with the common disorder that causes breathing disruption while sleeping.
Newsweek
14 minutes ago
- Newsweek
Weight Loss Drugs Like Ozempic Could Have Additional Health Benefit
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Could diabetes and weight loss drugs like Ozempic (semaglutide) also protect the brain from stroke damage—or even help prevent strokes entirely? Three new studies suggest they might, with the potential of GLP-1 receptor agonists—such as Ozempic—extending beyond just blood sugar regulation and weight loss. According to a May 2024 KFF Health Tracking Poll, approximately one in eight U.S. adults (12 percent) report having used a GLP-1 agonist. Usage rates are notably higher among individuals with chronic health conditions: 43 percent of adults with diabetes, 25 percent with heart disease, and 22 percent of those who have been diagnosed as overweight or obese in the past five years have taken one of these medication. Now, emerging research suggests they may also offer significant neurological benefits. A stock image of woman injecting a Semaglutide Pen in her stomach. A stock image of woman injecting a Semaglutide Pen in her stomach. JNemchinova/iStock / Getty Images Plus Lower Stroke Mortality in Ozempic Users The first study, led by researchers at the University of Wisconsin-Madison, analyzed stroke outcomes among patients taking Ozempic. The team compared data from two large sources: the University of Wisconsin's health system and a global health collaborative. Among more than two million stroke patients from the global dataset, those on Ozempic were found to have a dramatically lower initial death rate—just 5.26 percent compared to 21.61 percent for non-users. Long-term survival rates also favored Ozempic users, with a 77.5 percent survival rate versus 30.95 percent for those not on the drug. The university's own data mirrored this trend: stroke mortality among Ozempic users was less than 5 percent, compared to more than 26 percent in non-users. Could Ozempic Reduce the Risk of Stroke? A second study, also from the University of Wisconsin-Madison, looked at whether Ozempic could lower the chance of experiencing a stroke in the first place. Researchers analyzed emergency department records nationwide, identifying individuals likely using Ozempic and comparing their stroke incidence rates. The study found that potential Ozempic users had significantly lower odds of suffering a stroke. The research team now hopes to confirm these findings using pharmacy records, which would more precisely track who is prescribed the drug. Brain Bleed Protection and Cognitive Benefits The final study, conducted by the University of Texas Medical Branch in Galveston, extended the investigation to brain hemorrhages—both spontaneous bleeds and those caused by aneurysms. The researchers examined the health record of patients who had experienced a stroke or hemorrhage for up to two years after the event in question. Their analysis indicated that GLP-1 agonists were associated with reduced risks of cognitive decline, seizures, repeat hemorrhages and death. "This research could introduce a new perspective to the discussion of preventing and mitigating the devastating effects of stroke and related brain injuries," paper author and neurosurgeon Dr. Matias Costa said in a statement. A Promising Frontier for GLP-1 Drugs Dr. Ahmed Elbayomy, a research fellow in neurological surgery at the University of Wisconsin-Madison and lead author on two of the studies said in a statement: "More research is certainly needed, but seeing the potential protection offered by these medications is a fascinating finding." As use of semaglutide-based drugs like Ozempic and Wegovy continues to expand, the possibility that they might also protect the brain could usher in a new era of neurological prevention—offering more than just metabolic benefits. Do you have a tip on a health story that Newsweek should be covering? Do you have a question about GLP-1 agonists? Let us know via health@
Yahoo
33 minutes ago
- Yahoo
FDA approves SetPoint's neuroimmune modulation device for RA treatment
The US Food and Drug Administration (FDA) has approved SetPoint Medical's implantable neuroimmune modulation device, SetPoint System, to treat moderate-to-severe rheumatoid arthritis (RA) in adults. The system is designed for individuals who are inadequately managed by or intolerant to current RA therapies such as biological and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs). The system is said to activate the body's natural anti-inflammatory and immune-restorative pathways by delivering electrical stimulation to the vagus nerve once a day. The neurostimulation therapy can potentially provide an alternative treatment without immune-compromising risks. The FDA approval was based on the outcomes of the RESET-RA study, a 242-patient double-blind, randomised, sham-controlled trial, which showed the system's efficacy and safety in this patient group. Patients tolerated the device placement procedure and the stimulation therapy well, with a low incidence of related serious adverse events at 1.7%. SetPoint Medical CEO Murthy Simhambhatla said: 'The approval of the SetPoint System, the first-in-class neuroimmune modulation platform, represents a transformative milestone in the management of autoimmune diseases. 'We are committed to improving the health of people living with RA, and look forward to working with providers and payers to make our innovative therapy accessible to their patients. We plan to introduce the SetPoint System in targeted US cities this year, followed by expansion across the country starting in early 2026.' SetPoint Medical is also exploring the use of its neuroimmune modulation platform for other autoimmune diseases such as multiple sclerosis (MS) and Crohn's disease. In March 2024, the company's neuroimmune modulation device secured a breakthrough device designation to treat relapsing-remitting MS. "FDA approves SetPoint's neuroimmune modulation device for RA treatment" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
